Desonide is a corticosteroid sold in the U.S. under 4 brand and generic names, for facial dermatoses, foot dermatoses and hand dermatoses. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Desonide (application ANDA075751). Other desonide products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Desonide ointment USP, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide ointment USP, 0.05% should not be used with occlusive dressings.
In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide ointment USP, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals, Inc. at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Desonide ointment USP, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Topical | Generic | $0 | View → | |
| 2 | Not yet rated | Prescription | Topical | Generic | $0 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| 720 | 3 mg | orange, white | capsule | — |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Budesonide Inhalation Suspension
Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the ampoule solution
SUN PHARMACEUTICAL INDUSTRIES INC · May 29, 2026
Budesonide Inhalation Suspension
Lack of Assurance of Sterility: A market complaint was received for leakage and empty ampoule.
Cipla USA, Inc. · Jun 30, 2025
Airsupra (albuterol and budesonide) inhalation aerosol
Defective delivery system
AsttraZeneca Pharmaceuticals LP · May 14, 2025
Budesonide, USP (Micronized), 500 mg, White to off-white odorless, crystalline p…
CGMP Deviations and Presence of Particulate Matter: Glass
Medisca Inc. · Jun 26, 2024
Budesonide Extended-Release Tablets
Failed Dissolution Specifications
Golden State Medical Supply Inc. · Jan 12, 2024
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
| 3 | Not yet rated | Prescription | Topical | Generic | $0 | View → |
| 4 | Not yet rated | Prescription | Topical | Generic | $0 | View → |